Showing results (111-120 of 198) with videos related to

Sort By:
Pageof 20
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
Orphanet Journal of Rare Diseases|February 18, 2025
Health outcomes and drug utilisation in children with Noonan syndrome: a European cohort studyMichele Santoro, Ingeborg Barisic, Alessio Coi, et al.
European Journal of Human Genetics : EJHG|January 12, 2012
Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in EuropeDiana Wellesley, Helen Dolk, Patricia A Boyd, et al.
Cardiology in the Young|August 31, 2016
The changing epidemiology of Ebstein's anomaly and its relationship with maternal mental health conditions: a European registry-based studyBreidge Boyle, Ester Garne, Maria Loane, et al.
European Journal of Epidemiology|July 8, 2015
Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based studyAnthony Wemakor, Karen Casson, Ester Garne, et al.
Acta Paediatrica (Oslo, Norway : 1992)|February 7, 2024
Higher risk of cerebral palsy, seizures/epilepsy, visual- and hearing impairments, cancer, injury and child abuse in children with congenital anomalies: Data from the EUROlinkCAT studyStine Kjaer Urhoj, Joan Morris, Maria Loane, et al.
Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.
Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
British Journal of Haematology|December 4, 2018
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysisJennifer R Brown, Javid Moslehi, Michael S Ewer, et al.
Pageof 20